UNSPSC 51294518: Femoxetine hydrochloride

This classification denotes a serotonin agonist with the molecular formula C20H25NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2P1X5BE0XG, chemically known as piperidine, 3-((4-methoxyphenoxy)methyl)-1-methyl-4-phenyl-, (3r-trans)- but more generally known as femoxetine hydrochloride, which bears US NIH Compound Identifier 43103. European Medicines Agency schedules Femoxetine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02108MIG.

Most nations, for tariff and trade purposes, schedule femoxetine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, FEMOXETINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@@H]([C@H](C1)COC2CCC(CC2)OC)C3CCCCC3.CL.

UNSPSC 51294518 Femoxetine hydrochloride is a Commodity code that nominally addresses a specific pharmaceutical active ingredient, but recent state and local solicitation activity does not center on femoxetine itself. Instead, the code appears to be tagged to broader pharmaceutical procurement opportunities, including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and therapeutic pharmacy initiatives. State and local governments pursuing pharmaceutical procurement range across county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances. The scope of work encompasses acquisition of finished pharmaceutical products through established distribution channels, compliance with FDA requirements and Drug Supply Chain Security Act standards, and management of recurring inventory to support community health programs and employee benefit plans.

Recent opportunities reflect activity primarily in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with responses due July 26, 2023, and contract terms of two years with one-year renewal options. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP in January 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with awards effective July 1, 2026 and a two-year initial term. The Texas Health and Human Services Commission issued a preliminary Request for Information in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, indicating exploratory procurement activity that may lead to formal solicitation. Pharmaceutical vendors pursuing state and local opportunities must maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, substantive insurance coverage, and contractual relationships with established wholesale distributors.